NCT00039442View on ClinicalTrials.gov

Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 29, 2002

Primary Completion Date

December 7, 2005

Conditions
Cervical AdenocarcinomaCervical Adenosquamous CarcinomaRecurrent Cervical Carcinoma
Interventions
DRUG

Capecitabine

Given orally

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

85012

Gynecologic Oncology Group of Arizona, Phoenix

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT00039442 - Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer | Biotech Hunter | Biotech Hunter